CN103796661A - 用于维持骨骼健康以及治疗骨关节炎和关节的骨关节病的组合物 - Google Patents
用于维持骨骼健康以及治疗骨关节炎和关节的骨关节病的组合物 Download PDFInfo
- Publication number
- CN103796661A CN103796661A CN201280033364.9A CN201280033364A CN103796661A CN 103796661 A CN103796661 A CN 103796661A CN 201280033364 A CN201280033364 A CN 201280033364A CN 103796661 A CN103796661 A CN 103796661A
- Authority
- CN
- China
- Prior art keywords
- herba
- bone
- compositions
- composition
- plant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 23
- 230000037180 bone health Effects 0.000 title claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 29
- 241000196324 Embryophyta Species 0.000 claims abstract description 22
- 235000016551 Potentilla erecta Nutrition 0.000 claims abstract description 8
- 240000000103 Potentilla erecta Species 0.000 claims abstract description 8
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 7
- 230000012010 growth Effects 0.000 claims abstract description 7
- 240000004371 Panax ginseng Species 0.000 claims abstract description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 6
- 235000008434 ginseng Nutrition 0.000 claims abstract description 6
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 5
- 240000008042 Zea mays Species 0.000 claims abstract description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 5
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 claims abstract description 4
- 235000018185 Betula X alpestris Nutrition 0.000 claims abstract description 4
- 235000018212 Betula X uliginosa Nutrition 0.000 claims abstract description 4
- 235000005940 Centaurea cyanus Nutrition 0.000 claims abstract description 4
- 240000004385 Centaurea cyanus Species 0.000 claims abstract description 4
- 235000006386 Polygonum aviculare Nutrition 0.000 claims abstract description 4
- 244000292697 Polygonum aviculare Species 0.000 claims abstract description 4
- 235000000539 Rosa canina Nutrition 0.000 claims abstract description 4
- 240000008530 Rosa canina Species 0.000 claims abstract description 4
- 235000010337 Rosa dumalis Nutrition 0.000 claims abstract description 4
- 241000124033 Salix Species 0.000 claims abstract description 4
- XCGZWJIXHMSSQC-UHFFFAOYSA-N dihydroquercetin Natural products OC1=CC2OC(=C(O)C(=O)C2C(O)=C1)c1ccc(O)c(O)c1 XCGZWJIXHMSSQC-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 4
- 239000011707 mineral Substances 0.000 claims abstract description 4
- 230000011164 ossification Effects 0.000 claims abstract description 4
- 229960001285 quercetin Drugs 0.000 claims abstract description 4
- 235000005875 quercetin Nutrition 0.000 claims abstract description 4
- 229940087164 tormentil Drugs 0.000 claims abstract description 4
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims abstract description 3
- 241000508725 Elymus repens Species 0.000 claims abstract description 3
- 235000003230 Helianthus tuberosus Nutrition 0.000 claims abstract description 3
- 240000008892 Helianthus tuberosus Species 0.000 claims abstract description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000008523 Smilax herbacea Nutrition 0.000 claims abstract description 3
- 208000018631 connective tissue disease Diseases 0.000 claims abstract description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims abstract description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims abstract description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims abstract description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000005493 rutin Nutrition 0.000 claims abstract description 3
- 229960004555 rutoside Drugs 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 29
- 241001465754 Metazoa Species 0.000 claims description 20
- 239000000654 additive Substances 0.000 claims description 11
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 10
- 230000000996 additive effect Effects 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 9
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 235000013406 prebiotics Nutrition 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 241000628997 Flos Species 0.000 claims description 6
- 206010065687 Bone loss Diseases 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 5
- 150000002337 glycosamines Chemical class 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 4
- 230000000975 bioactive effect Effects 0.000 claims description 4
- 235000005822 corn Nutrition 0.000 claims description 4
- 244000175269 Smilax herbacea Species 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 230000000050 nutritive effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims description 2
- 235000005983 Crescentia cujete Nutrition 0.000 claims description 2
- 244000241257 Cucumis melo Species 0.000 claims description 2
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims description 2
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 claims description 2
- 244000067676 Gnaphalium affine Species 0.000 claims description 2
- 244000308760 Helichrysum petiolatum Species 0.000 claims description 2
- 235000009797 Lagenaria vulgaris Nutrition 0.000 claims description 2
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 claims description 2
- 241000044532 Paspalum conjugatum Species 0.000 claims description 2
- 244000110797 Polygonum persicaria Species 0.000 claims description 2
- 235000004442 Polygonum persicaria Nutrition 0.000 claims description 2
- 235000005794 Salvia japonica Nutrition 0.000 claims description 2
- 244000295490 Salvia japonica Species 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 244000299461 Theobroma cacao Species 0.000 claims description 2
- 235000009470 Theobroma cacao Nutrition 0.000 claims description 2
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 210000001161 mammalian embryo Anatomy 0.000 claims description 2
- 240000009087 Crescentia cujete Species 0.000 claims 1
- 238000005457 optimization Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 230000008929 regeneration Effects 0.000 abstract description 13
- 238000011069 regeneration method Methods 0.000 abstract description 13
- 210000002808 connective tissue Anatomy 0.000 abstract description 8
- 208000010392 Bone Fractures Diseases 0.000 abstract description 3
- 206010017076 Fracture Diseases 0.000 abstract description 3
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 abstract description 2
- 244000307697 Agrimonia eupatoria Species 0.000 abstract description 2
- 240000002234 Allium sativum Species 0.000 abstract description 2
- 240000005528 Arctium lappa Species 0.000 abstract description 2
- 235000003130 Arctium lappa Nutrition 0.000 abstract description 2
- 235000008078 Arctium minus Nutrition 0.000 abstract description 2
- 235000011330 Armoracia rusticana Nutrition 0.000 abstract description 2
- 240000003291 Armoracia rusticana Species 0.000 abstract description 2
- 208000006820 Arthralgia Diseases 0.000 abstract description 2
- 235000007319 Avena orientalis Nutrition 0.000 abstract description 2
- 244000104272 Bidens pilosa Species 0.000 abstract description 2
- 235000003880 Calendula Nutrition 0.000 abstract description 2
- 240000001432 Calendula officinalis Species 0.000 abstract description 2
- 235000007542 Cichorium intybus Nutrition 0.000 abstract description 2
- 244000298479 Cichorium intybus Species 0.000 abstract description 2
- 241001137883 Cucumaria Species 0.000 abstract description 2
- 235000009419 Fagopyrum esculentum Nutrition 0.000 abstract description 2
- 240000008620 Fagopyrum esculentum Species 0.000 abstract description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 abstract description 2
- 244000062730 Melissa officinalis Species 0.000 abstract description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract description 2
- 244000038697 Potentilla palustris Species 0.000 abstract description 2
- 235000016553 Potentilla palustris Nutrition 0.000 abstract description 2
- 241000320380 Silybum Species 0.000 abstract description 2
- 235000010841 Silybum marianum Nutrition 0.000 abstract description 2
- 244000197975 Solidago virgaurea Species 0.000 abstract description 2
- 235000000914 Solidago virgaurea Nutrition 0.000 abstract description 2
- 240000001949 Taraxacum officinale Species 0.000 abstract description 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 abstract description 2
- 244000078534 Vaccinium myrtillus Species 0.000 abstract description 2
- 244000144987 brood Species 0.000 abstract description 2
- 229940070641 chamomile flowers Drugs 0.000 abstract description 2
- 235000000125 common agrimony Nutrition 0.000 abstract description 2
- 235000004611 garlic Nutrition 0.000 abstract description 2
- 235000002020 sage Nutrition 0.000 abstract description 2
- 235000015763 Artemisia ludoviciana Nutrition 0.000 abstract 1
- 241000209763 Avena sativa Species 0.000 abstract 1
- 235000007558 Avena sp Nutrition 0.000 abstract 1
- 235000000832 Ayote Nutrition 0.000 abstract 1
- 235000010662 Bidens pilosa Nutrition 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 240000004244 Cucurbita moschata Species 0.000 abstract 1
- 235000009854 Cucurbita moschata Nutrition 0.000 abstract 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 abstract 1
- 240000003173 Drymaria cordata Species 0.000 abstract 1
- 240000008306 Euphorbia tithymaloides Species 0.000 abstract 1
- 235000016970 Fragaria moschata Nutrition 0.000 abstract 1
- 244000307700 Fragaria vesca Species 0.000 abstract 1
- 235000014828 Fragaria vesca ssp. americana Nutrition 0.000 abstract 1
- 235000012660 Fragaria virginiana Nutrition 0.000 abstract 1
- 240000004859 Gamochaeta purpurea Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 241000608847 Gnaphalium Species 0.000 abstract 1
- 244000141009 Hypericum perforatum Species 0.000 abstract 1
- 235000002598 Inula helenium Nutrition 0.000 abstract 1
- 244000116484 Inula helenium Species 0.000 abstract 1
- 235000013421 Kaempferia galanga Nutrition 0.000 abstract 1
- 244000062241 Kaempferia galanga Species 0.000 abstract 1
- 235000010654 Melissa officinalis Nutrition 0.000 abstract 1
- 244000010922 Plantago major Species 0.000 abstract 1
- 241000219000 Populus Species 0.000 abstract 1
- 235000009108 Urtica dioica Nutrition 0.000 abstract 1
- 244000274883 Urtica dioica Species 0.000 abstract 1
- 235000013832 Valeriana officinalis Nutrition 0.000 abstract 1
- 244000126014 Valeriana officinalis Species 0.000 abstract 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 abstract 1
- 230000008468 bone growth Effects 0.000 abstract 1
- 230000010478 bone regeneration Effects 0.000 abstract 1
- 235000015827 common plantain Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 235000009973 maize Nutrition 0.000 abstract 1
- 235000015136 pumpkin Nutrition 0.000 abstract 1
- 235000016788 valerian Nutrition 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 description 36
- 239000000047 product Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 239000000843 powder Substances 0.000 description 12
- 208000012659 Joint disease Diseases 0.000 description 11
- 235000016709 nutrition Nutrition 0.000 description 11
- 230000036770 blood supply Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 210000001612 chondrocyte Anatomy 0.000 description 8
- 239000000419 plant extract Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 230000035764 nutrition Effects 0.000 description 7
- 210000001179 synovial fluid Anatomy 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 230000000529 probiotic effect Effects 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 235000019160 vitamin B3 Nutrition 0.000 description 5
- 239000011708 vitamin B3 Substances 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 210000004394 hip joint Anatomy 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000000629 knee joint Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- -1 reopirine Chemical compound 0.000 description 4
- 210000005065 subchondral bone plate Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003042 chondroprotective agent Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229960002849 glucosamine sulfate Drugs 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000055008 Matrilin Proteins Human genes 0.000 description 2
- 108010072582 Matrilin Proteins Proteins 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008414 cartilage metabolism Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000004459 forage Substances 0.000 description 2
- 150000002301 glucosamine derivatives Chemical class 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000037231 joint health Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000005499 meniscus Effects 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940034208 thyroxine Drugs 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 244000204909 Anoda cristata Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 208000017234 Bone cyst Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000003759 Erodium cicutarium Species 0.000 description 1
- 235000009967 Erodium cicutarium Nutrition 0.000 description 1
- 241001337814 Erysiphe glycines Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 241000700189 Hystrix <Rodentia> Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000132446 Inula Species 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 240000007741 Lagenaria siceraria Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000100287 Membras Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- 241000210050 Potentilla alba Species 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 208000020307 Spinal disease Diseases 0.000 description 1
- 240000006694 Stellaria media Species 0.000 description 1
- 241000219422 Urtica Species 0.000 description 1
- 241000792914 Valeriana Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000007316 Xerochrysum bracteatum Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001537 electron coincidence spectroscopy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000020187 evaporated milk Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000002061 histotrophic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 230000010438 iron metabolism Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000009943 skeletal muscle blood flow Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000017468 valeriana Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Physiology (AREA)
- Birds (AREA)
- Insects & Arthropods (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
Abstract
本发明涉及用于预防、治疗和缓解结缔组织疾病的组合物。该组合物包含以下成分:植物、雄蜂子,槲皮素,二氢槲皮素和芦丁。所使用的植物可以是:牛蒡、蒲公英、沼委陵菜、桦树、金丝桃(St.John′s wort)、一枝黄花、荨麻、薄荷、甘草、委陵菜、直立委陵菜、犬蔷薇、花葱(Jacob′s Ladder)、缬草、玉米、瓜参、奶蓟、燕麦、仙鹤草、蜡菊、人参、鼠尾草、繁缕、葫芦、柳树、泡草莓、菊苣、茅草、洋姜、越橘、金盏花、辣根、大蒜、杨树、两耳草、车前草、土木香(elecampane)、红荞、洋甘菊花、蜜蜂花、高良姜(galangal)、矢车菊、鼠麴草、金盏花(bur marigold)。该组合物用于缓解或预防骨骼疾病,治疗骨关节炎和骨质疏松,增加骨生长过程中的骨形成和骨矿物质密度,优化峰值骨量,在骨折愈合过程中刺激骨再生,减少骨质疏松。该组合物可以有效地消除关节疼痛,滋养骨关节系统,促进结缔组织的生长和再生,而且没有副作用。
Description
本发明的描述
本发明涉及用于改善运动系统的功能状态的组合物,其为一种控制关节疾病的现代和有效的方式。本发明还涉及该组合物在生产营养产品、添加剂或药物和在刺激软骨组织修复方法中的应用,所述方法包含摄取有效量的这种组合物。本发明的组合物可以用于生产用于人或家畜的营养产品、添加剂、治疗用品或药物,促进哺乳动物的软骨形成,预防家畜或人的骨关节炎,从而增强个体的活动或行动。根据另一个方面,本发明涉及植物或植物提取物在制备用于维持哺乳动物骨健康和预防、缓解和/或治疗骨疾病的组合物中的应用,所述的植物或植物提取物基于其刺激骨形态发生蛋白(bone morphogenic protein)和/或抑制骨质吸收的能力来选择。此外,本发明提供了用于预防、缓解和/或治疗骨疾病或维持骨健康的方法,该方法提高了治疗功效并防止了并发症和副作用发生,所述方法包括施用有效量的所述组合物。本发明还涉及治疗、缓解和/或预防家畜或人的骨关节炎的方法,该方法包括用这种组合物饲喂个体的步骤。
百年的医学实践表明,几乎所有人都会偶尔背痛和四肢关节痛(R.Nordemar,Back Pain-Moscow:Meditsina,1988-144pp全文 1988-144c)。3%的世界人口出现类风湿性关节炎,这是炎症性关节疾病的最严重形式,同时大约10%的世界人口出现非炎症性(退行性)的变化(如关节病)(V.P. Kessel,When Joints Ache,-Moscow:Zaniye,1979-96pp全文cycTaBbI,-M.:1979.-96c)。
目前用来治疗关节疾病的有不同的药物产品(urodan、阿司匹林、reopirine、双氯芬酸、安乃近、抗生素等),所述产品不具有足够的效力。已知有超过100种非特异性药物用于治疗关节疾病,但由于治疗效力不足和长期效果差的问题还远未得到解决,因此称为药物泛滥还为时过早。
骨关节炎(OA)是一种渐进的慢性疾病,其主要影响大部分机体应激的关节,如髋关节和膝关节。这种情况涉及影响整个关节,导致一系列的破坏和重建的过程,不可避免地影响到关节的解剖结构和功能,因而影响所有的关节成分,如软骨、软骨下骨和滑膜组织。因此OA是系统性因素(如年龄或肥胖)和局部因素(例如,创伤或高度压力)之间的相互作用的结果,由此受到很多触发因素调节,可能是不同病因的感染或炎症过程的组合。过去认为软骨负责OA的发生并且作为唯一的靶器官。然而,最近得到的大量数据表明软骨下骨可能作为负责OA的发生和发展的致病因素。
综合考虑下这些情况,很多年来,人们致力于通过去除单个因果进程和使用局部或全身的抗炎药物,或关节腔内注射透明质酸来处理这情况。后来有人建议使用制剂影响骨代谢,如双膦酸盐。而通过非正式方式描述的一些药物如软骨保护剂(蒽醌类、软骨素硫酸盐等),同样应用有限,但其实际的治疗能力是非常低和有争议的。
已经确立,软骨下骨结构的形态学变化先于关节软骨损伤。在软骨下关节区域中的微循环异常的特征在于静脉流出阻塞并且伴随着骨内压增高,这导致极度痛苦的疼痛综合征。
已知具有免疫调节、抗病毒、抗菌、抗氧化、膜稳定效果和刺激软骨和结缔组织再生作用的药物,其包含属于软骨保护剂的物质,即硫酸软骨素硫酸和葡糖胺,以及抗菌成分和具有佐剂的赋形剂(专利No.2349339,RU.公开日2009.03.20)。已知用于治疗关节疾病的药物,其包含硫酸软骨素、二甲亚砜、防腐剂、乳胶基质如(专利No.2353349,RU.公开日2009.04.27)。已知用于治疗关节疾病的药物,其含有葡糖胺盐、硫酸软骨素盐和二甲亚砜(专利No.2239438,RU,公开日2006.03.20和专利No.6528,EA-模拟。公开日2006.02.24)。已知用于治疗和预防运动系统的治疗和预防的一种药物“硫酸葡糖胺”(Biologically Active Food Supplements.-Moscow:Nauka,2002年,第47页-M.:HayKa,2002,c.47)。“硫酸葡糖胺”制剂包含葡糖胺。葡糖胺有软骨保护作用。进入人体时,它被递送到软骨及其他组织,在那里转化成硫酸软骨素。硫酸软骨素用作结缔组织结构材料的主要来源。它参与关节软骨、韧带、肌腱的形成,存在于血管和支气管壁、皮肤和黏膜上。硫酸软骨素是再生软骨组织和形成滑膜液的有效方式,以降低肌肉疲劳,同样加强任何人体中的结缔组织。然而,“硫酸葡糖胺”是一个单体药物。已知称为“Sustavite”(“CycTa B)的药物,其包含用于治疗和预防的组合成分,其中,除了葡糖胺衍生物外,还包括硫酸软骨素、药用植物、维生素、钙和酶(Biologically Active Food Supplements.-Moscow:Nauka,2002年,第49页-M.:Hayκa,2002,c.49)。已知组合物提供支持骨关节系统的营养,促进结缔组织的生长和再生及刺激胶原蛋白产生和软骨生长必需的物质,它代表了本发明的最接近的现有技术。
这些已知药物的缺点在于它们缺少能提高静脉系统张力、改善静脉流量、由此减弱腿部中与关节疾病相关的沉重感和肿胀的活性物质。
本发明的目的在于提供具有有效地消除关节中的疼痛综合征的作用的活性物质组合物。
本发明的目的在于提供组合物,它能有效地为骨关节系统和结缔组织的生长和再生提供营养支持,而没有副作用。
本发明的目的在于通过保持抗炎和镇痛效果使结缔组织、软骨组织的再生提供可能的胶原合成。
通过所述组合物实现这一系列目标,所述组合物包括:
复杂的天然物质,其基于:
植物,产生软骨组织再生的因子(苷类,例如真正的软骨保护剂蒲公英苦素(taraxacine)、蒲公英素(taraxacerine),维生素PP)。苷类的药理作用应是,一方面,提供软骨细胞增殖并改变软骨基质的状态,另一方面,维生素PP(烟酸,维生素B3,烟酸,维生素PP)属于B族维生素并参与氧化还原过程、蛋白质代谢、碳水化合物代谢、胆固醇代谢、铁代谢,并且代表了唯一参与激素状态建立的维生素。维生素PP在合成性激素(雌激素、孕酮、睾酮)以及由肾上腺皮质(可的松)、甲状腺(甲状腺素)和胰腺(胰岛素)产生的激素中起着至关重要的作用。可的松、甲状腺素、胰岛素对软骨再生并形成组织的软骨细胞有积极影响。生长激素的释放引起肝脏中胰岛素样生长因子(IGF-1)的合成,这显然是在骨、骨髓、软骨和滑液再生中的最强的合成代谢。
雄蜂子(Drone brood),其是雄激素类固醇的贡献者,雄性激素类固醇有催乳素、雌二醇、孕酮、睾酮。在氨基酸中,即甘氨酸、丙氨酸等,对软骨细胞(软骨细胞)的形成和滑液补给具有刺激作用。
植物化学化合物,其恢复代谢过程,增强毛细血管的通透性,改善骨组织的血液供应,从而使软骨再生并修复其结构。
基本概念
健康的关节以及一个有机体是由活细胞构成的。骨骼、软骨、半月板及其它关节组织由活细胞组成。只有活细胞能够再生和全面恢复,认为腿部关节特别难以治愈。处理关节疾病,无论是关节病、关节炎、多关节炎还是半月板脱离,都有需要知道是什么原因导致疾病转为慢性的。
已知关节是由表面覆有软骨组织的骨关节而形成。当做各种动作时,软骨充当减震器,减少对连接骨表面的压力并使其相对对方滑动顺畅。
软骨重复数千次并灵活响应一成不变的动作:在行走或跑步、跳跃时做推的动作等。这种重复应力导致一部分纤维老化和毁坏。健康的关节通过产生等量的新纤维来补偿这些损失。软骨组织再生所需要的新构成材料的合成及其毁坏之间出现不平衡时,导致出现关节和脊柱疾病。
这一发现使人们能够重新审视关节疾病的问题,并把它与代谢性疾病相关联。此外,有人证明,后者实际上表现为主要的原因,而伴随着后续疾病的骨关节系统的改变表现为次要原因。这也解释了为什么关节疾病在初期潜伏发展,无明显症状。不管疾病的阶段,代谢的靶向调节不仅能停止关节变形,而且还促进软骨形态学结构的再生。
软骨组织代表了一类在生物体中作为身体支撑起作用的结缔组织。除了关节软骨,软骨膜提供软骨的营养和生长,是不可缺少的软骨属性。关节中的软骨是“裸”的,并直接与关节内环境即滑液直接接触。它作为覆盖着平滑透明软骨的关节面之间滑动的一种润滑。骨和脊椎软骨不断经历着静态和动态的应力。
软骨细胞(软骨细胞)和由纤维和无定型的基质(ground substance)组成的细胞外基质是其主要成分。此外,软骨实际上主要是由细胞间质组成。软骨中有少数细胞,这些细胞被大量细胞外间隙即基质包围,这是软骨相对于其他类型的身体组织的一个显着特点。损伤后的软骨的恢复差是因为能够繁殖的细胞数量少,因此,主要由细胞外基质来决定它的修复(恢复)的发生。通过下面的对比,将证实软骨代谢活性低的程度。肝脏蛋白质组成在4(!)天中更新完全。
软骨胶原蛋白在10(!)年中只有50%更新。因此,可以理解任何软骨组织损伤几乎是无法治愈的,除非采取目标在于增加软骨细胞的数量的特别措施以形成新的基质。
关节软骨中含大量的水(一个年轻男子股骨头软骨中每100克组织含75克的水)。透明质酸促进基质与水结合,从而使组织具有弹性和弯曲性能。
下列作为再生的来源:1)软骨本身;2)关节滑膜,在缺陷边缘生长过度并转化为软骨样组织;3)骨细胞,值得注意的是,其来源于软骨并在必要时能变换“回”在结构上类似于软骨的组织;4)骨髓细胞,其可以作为损伤软骨在与损伤骨结合的深处再生的来源。
骨的血流量是相当密集的,骨组织具有5%的心脏血液输出。血流速度仅低于大脑中2倍以下。因此骨组织的命运、形成及其破坏依赖于血液供应、一系列的充血、充血性的和贫血状况。骨血流与骨骼肌血流类似,但是,考虑到骨在很大程度上是由无机物质(结合钙的盐)组成,每1骨块的骨细胞的血流量比在肌肉中的高。在一定意义上,骨上具有较高的代谢活性和血液供应,以活跃细胞重量为基准测量,比肌肉的血液供应的10倍还高(G.I.Lavrishcheva等,“骨骼的血液供应和再生”(Bone Blood Supply and Regeneration),Kishinev,“Shtinnitsa”,1981 1981r)。因此,任何异常骨的血液供应导致骨、骨髓、软骨、滑膜液变得营养不良。相反,由于增加毛细血管的通透性导致的血液供应会改善增强骨、骨髓、软骨、滑膜液的再生。
本发明的组合物:
一方面,药理作用应诱导软骨细胞增殖,并且,在另一方面,改变软骨基质的状态,并修复骨和软骨组织周围的胶原骨架,改善血液供应,促进骨、骨髓、软骨、滑膜液再生。
用于预防,治疗和缓解结缔组织疾病病程的组合物由选自以下组中的一种、两种或三种成分组成:
1)植物:该组合物包括用于预防、缓解和/或治疗骨疾病和维持人和家畜骨健康的植物,该组合物含有有效量的作为活性成分的至少一种植物(或植物提取物)或多种植物(或植物提取物),其选自:牛蒡(burdock)、蒲公英(dandelion)、沼委陵菜(marsh cinquefoil)、桦木(birch)、金丝桃(Hypericum)、一枝黄花(goldenrod)、荨麻(Urtica)、薄荷(mint)、甘草Glycyrrhiza、白花委陵菜(Potentillaalba)、洋委陵菜(Potentilla erecta)、犬蔷薇(dogrose)、花葱(Polemoniumcaeruleum)、缬草(Valeriana)、玉米(corn)、瓜参(Cucumaria)、奶蓟(milk thistle)、燕麦(oats)、仙鹤草agrimony、蜡菊(immortelle)、人参(ginseng)、鼠尾草(sage)、繁缕(Stellaria)、葫芦(gourd)、柳(Salix)、草莓(strawberries)、菊苣(chicory)、偃麦草(Elytrigia)、洋姜(sunroot)、越橘(bilberry)、金盏花(calendula)、辣根(horseradish)、大蒜(garlic)、白杨(aspen)、结草(birdweed)(两耳草(knot-grass))、车前草(plantains)、旋覆花(Inula)、红茎荞麦(redstem buckwheat)、洋甘菊花(chamomile flowers)、蜜蜂花(Melissa)、直立委陵菜(tormentil)、矢车菊(bluecornflower)、鼠麴草(cottonweed)、狼把草(bur beggar-tick)。如本文所用,“植物”是指其任意部分,即叶、块茎、果实、种子、根、谷物(grain)、胚或细胞培养物。植物或植物提取物可以是来自叶、根和/或果实的冻干提取物,这取决于所用植物的物种,或新鲜收获的植物,或用无机或有机溶剂通过本领域中已知的方法的萃取法得到的富集馏分。
2)雄蜂子,可以是下列物质:雄蜂幼虫(drone larvae),或雄蜂幼虫的冻干提取物,或用本领域中已知的方法用无机或有机溶剂通过萃取法得到的浓缩部分,或它们的组合。
3)植物化学化合物,例如一种物质,其含有从以下组中选择的一种或多种物质:槲皮素(quercetine)、二氢槲皮素、芦丁。
本发明的组合物可以用于食品组合物的制造。所述组合物既可以是营养平衡食品也可以是家畜的饲料或营养添加剂、治疗或药物制剂的形式。
该组合物可单独使用,也可与其他植物组合使用,诸如菊苣、茶、可可,或与其他生物活性分子组合使用,如抗氧化剂、脂肪酸、益生元纤维、葡糖胺、硫酸软骨素。
在一个实施方案中,制备了用于人类消费的食品组合物。所述组合物可以完全是均衡的营养制剂、乳制品、冷却或长寿命饮料、汤、营养添加剂、日常饮食中的代餐和营养棒或糖食。
营养制剂优选使用肠内给药,例如作为粉末、片剂、胶囊、液体浓缩物、固体产品或即饮饮品。为了制备干粉营养制剂,将均匀的混合物从适合的干燥器中通过,例如,喷雾干燥器或冷冻干燥器,从而得到粉末。
在另一个实施方案中,所述营养组合物包含基于牛奶的混合了益生元制剂的谷物产品。所述基于牛奶的谷物的产品优选是婴儿食品,其可以作为益生元配方的载体。
在另一个实施方案中,可以用本发明中的至少一种植物或植物提取物来丰富常见的食品,例如发酵乳制品、酸奶、新鲜乳酪、凝乳、糖食、甜的或甜饮料、糖果棒、麦片或早餐谷物棒、饮料、脱水牛奶、基于大豆的产品、非乳类发酵品或临床中的膳食用营养添加剂。
根据所用的植物物种及其部分的不同,组合物中的植物或植物提取物的量可以变化。在优选的实施方案中,有效的日剂量至少为1mg左右,更优选1mg至200mg的活性分子。
在一个实施方案中,可以制备包含如上所述的化合物的药物组合物,其中化合物的用量足以在个体中达到期望的效果。所述组合物可以是片剂、液体、胶囊剂、软胶囊剂、糊剂或锭剂、口香糖或可饮用溶液或乳剂、干的口服添加剂、湿口服添加剂的形式。该药物组合物也将包括适合于递送各种性质的相应的活性分子到靶组织的载体和赋形剂。载体/赋形剂的类型和用量取决于物质的性质和预期的药物递送的方法和/或给药途径。显然,本领域技术人员在能够依靠他们的经验和知识选择适合的成分和药用形式。
本发明的用于家畜的营养平衡饲料组合物可以配制成粉末、干的形式,可以作为用于家畜的治疗产品也可以作为用于家畜潮湿,冷冻或常温稳定的产品。这可以是冷却后的产品或保质期长的产品。可以使用任何已知的方法来制备上述家畜用产品。
必要时,家畜的饲料组合物还可以包含益生元、益生菌微生物或另一种活性剂,例如,长链脂肪酸。优选地,在家畜的饲料组合物中的益生元的量少于10质量%。作为实例,益生元可以构成饲料重量的约0.1~5质量%。如果所述饲料包括作为益生元来源的菊苣,则可以添加菊苣,使其用量在饲料混合物中为0.5~10质量%左右,更优选1至5质量%左右。
在使用益生菌微生物的情况下,优选实施方案中1克的家畜饲料包含约104至10l0个细胞益生菌微生物,在更优选的实施方案中,约为106到108个细胞的益生菌微生物。家畜饲料可以含有大约0.5~20质量%的益生菌微生物的混合物,优选约为1至6质量%,例如,约3至6质量%。
如有必要,在家畜饲料中加入矿物质和维生素,这样它是完全营养均衡的。此外,如需要,家畜饲料中可以加入其他成分,如糖、盐、香料、药草、香料等。
在另一个实施方案中,可以制备改善家畜饲料质量的营养添加剂。这些营养添加剂可以被包封或制成粉剂,并与基础饲料包装在一起或单独包装,后者为潮湿或干燥的。作为实例,包含本发明提取物的粉末可以装在小药囊中或作为粉末,或以凝胶或脂质的形式,或装在任何其他合适的载体中。根据用户说明书,这些单独包装的添加剂可进一步与基础饲料一同提供,也可以在多个包装袋中供日后与基础饲料或治疗剂一起使用。
为实现预期的效果,家畜所消耗的饲料量将取决于家畜的大小,品种和年龄。然而,对于狗和猫的家畜饲料的用量,每kg动物体重提供约0.5至5g的干燥植物的每日剂量的用量一般是足够的。
在治疗骨折的过程中对人或家畜施用如上所述的食物组合物或饲料组合物会导致骨的再生改善。该组合物能在生长阶段刺激骨形成,优化骨矿物质密度。特别地,可以在儿童中提供最佳的骨生长。上述食品组合物有助于预防骨丢失,特别是与年龄相关的哺乳动物骨丢失或长期住院相关的骨丢失。它可以减少骨质疏松症的风险,改善骨折后的恢复。此外,它可以促进哺乳动物的软骨形成,可以防止人类和家畜的骨关节炎,因而导致个体的活动或行动增强。
下面提供的实施例仅用于示例本发明,但它们不是为了限制本发明的范围。
产品的制备实施例。
实施例1
成分:
-二氢槲皮素粉,10kg
-冻干雄蜂子,10kg
-研磨的蒲公英根粉,10kg。将混合物搅拌至均匀,然后封装得到的产物。
实施例2
成分:
-二氢槲皮素粉,100kg
-冻干雄蜂子,400kg
-研磨的蒲公英根粉500kg。将混合物搅拌至均匀,然后压片。
为开展实验,选择每1片的配方,其包括:二氢槲皮素100mg,冻干雄蜂子100mg,蒲公英根粉200mg。给药方案:周期,每次1片,每日2次,用30天之后,停14天。治疗持续时间为9个月。
本文提供的治疗方法已经用于“Sekrety dolgoletiya” Penza市的Medical Center的30例患有下肢骨关节病并发滑膜炎、肩周炎、软骨和骨质疏松症、静脉曲张、骨质疏松症的患者,他们年龄在54至72岁。病程1-10年。
发现患者经受腿痛,关节僵硬,关节活动受限,生活质量下降。体检显示膝关节区域、髋关节的超髋臼区域肿胀,膝关节畸形和变形,膝关节和髋关节区域的皮肤温度升高,以及其中的运动受限。
根据本发明方法的治疗导致所有患者的改善,即,膝关节和髋关节的疼痛减轻或消除,其中的活动范围增加,根据温度测量数据的皮肤温度降低。血流造影术(Rheovasography)和肌肉血液体积流速显示,患肢区域的血液供应改善,软骨下囊肿的形成未发生或延迟;患者的生活质量改善,并且推迟了体内假肢手术的必要性。
上述用于治疗具有骨关节病的并患有相关疾病的患者的方法改善了组织营养机能和软骨代谢和关节周围组织的代谢,使循环正常化,对受影响的肢体区域中软骨下骨重塑产生积极影响。给予组合物的第一个周期后发生改善。运动活动增加并且疼痛综合征缓解,从而导致持续缓解,患者的生活质量改善,推迟了体内假肢手术的必要性。
因此,该治疗方法改善了患者的生活质量,有助于预防患有骨关节病I-II初始阶段的患者的疾病的发展和残疾,并推迟该疾病III-IV级患者体内假肢手术的必要性。
Claims (10)
1.用于预防、治疗和缓解结缔组织疾病病程的组合物,该组合物由选自以下组的一种、两种或多种成分组成:
选自以下组的植物:牛蒡、蒲公英、沼委陵菜、桦木、金丝桃、一枝黄花、荨麻、薄荷、甘草、白花委陵菜、洋委陵菜、犬蔷薇、花葱、缬草、玉米、瓜参、奶蓟、燕麦、仙鹤草、蜡菊、人参、鼠尾草、繁缕、葫芦、柳、草莓、菊苣、偃麦草、洋姜、越橘、金盏花、辣根、大蒜、白杨、结草(两耳草)、车前草、旋覆花、红茎荞麦、洋甘菊花、蜜蜂花、直立委陵菜、矢车菊、鼠麴草、狼把草;
雄蜂子;
一种或多种选自以下组的物质:槲皮素,二氢槲皮素,芦丁。
2.根据权利要求1的组合物,其中所述的植物是指其任意部分,如,叶、块茎、果实、种子、根、谷物、胚或细胞培养物。
3.根据权利要求1的组合物,其中所述组合物是营养平衡食品或家畜的饲料、营养添加剂、治疗或药物组合物的形式。
4.根据权利要求1到3的应用,其中所述组合物可单独使用,也可与其他植物,如菊苣、茶和可可,或与其他生物活性分子,如抗氧化剂、脂肪酸、益生元纤维、葡糖胺和硫酸软骨素,组合使用。
5.用于治疗、缓解或预防骨疾病或维持骨健康的方法,该方法包括施用有效量的权利要求1至3任一项的组合物。
6.用于增加人或家畜在生长阶段中的骨形成、骨矿物质密度和优化峰值骨量的方法,该方法包括用权利要求1至3任一项的组合物饲喂个体的步骤。
7.用于治疗、缓解和/或预防人或家畜骨关节炎的方法,该方法包括用权利要求1至3任一项的组合物饲喂个体的步骤。
8.用于治疗或预防骨质疏松症的方法,该方法包括施用有效量的权利要求1至3任一项的组合物。
9.用于治疗骨折期间刺激骨再生的方法,该方法包括用权利要求1至3任一项的组合物饲喂个体的步骤。
10.用于减少人或家畜骨丢失、特别是与年龄相关的骨丢失的方法,该方法包括用权利要求1至3任一项的组合物饲喂个体的步骤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811490135.5A CN109364194A (zh) | 2011-07-05 | 2012-07-03 | 维持骨骼健康及治疗骨关节炎和关节的骨关节病的组合物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2011127494 | 2011-07-05 | ||
RU2011127494/15A RU2509569C2 (ru) | 2011-07-05 | 2011-07-05 | Композиция для лечения и предупреждения остеоартрита и остеоартроза суставов |
PCT/RU2012/000528 WO2013006094A2 (ru) | 2011-07-05 | 2012-07-03 | Композиция для поддержания здоровья костей, лечения остеоартрита, остеоартроза суставов |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811490135.5A Division CN109364194A (zh) | 2011-07-05 | 2012-07-03 | 维持骨骼健康及治疗骨关节炎和关节的骨关节病的组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103796661A true CN103796661A (zh) | 2014-05-14 |
Family
ID=47437595
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280033364.9A Pending CN103796661A (zh) | 2011-07-05 | 2012-07-03 | 用于维持骨骼健康以及治疗骨关节炎和关节的骨关节病的组合物 |
CN201811490135.5A Pending CN109364194A (zh) | 2011-07-05 | 2012-07-03 | 维持骨骼健康及治疗骨关节炎和关节的骨关节病的组合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811490135.5A Pending CN109364194A (zh) | 2011-07-05 | 2012-07-03 | 维持骨骼健康及治疗骨关节炎和关节的骨关节病的组合物 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20140287058A1 (zh) |
EP (1) | EP2730286B1 (zh) |
CN (2) | CN103796661A (zh) |
CA (1) | CA2840895A1 (zh) |
DK (1) | DK2730286T3 (zh) |
EA (1) | EA031357B1 (zh) |
ES (1) | ES2688368T3 (zh) |
HU (1) | HUE039880T2 (zh) |
IL (1) | IL230245B (zh) |
IN (1) | IN2014CN00428A (zh) |
PL (1) | PL2730286T3 (zh) |
PT (1) | PT2730286T (zh) |
RS (1) | RS57684B1 (zh) |
RU (1) | RU2509569C2 (zh) |
UA (1) | UA111615C2 (zh) |
WO (1) | WO2013006094A2 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104721678A (zh) * | 2014-07-12 | 2015-06-24 | 广东医学院 | 高良姜提取物在制备抗骨质疏松保健食品及药品方面的应用 |
CN106511336A (zh) * | 2016-12-16 | 2017-03-22 | 常州南京大学高新技术研究院 | Harrisotone A衍生物的组合物在抗骨质疏松药物中的应用 |
CN106615132A (zh) * | 2016-11-28 | 2017-05-10 | 山东坤泰生物科技有限公司 | 一种改善骨质疏松的配制型含乳饮料及其制备方法 |
CN109260514A (zh) * | 2018-08-31 | 2019-01-25 | 湖南大学 | 一种花旗松素改性纤维支架及其制备方法和应用 |
CN115023150A (zh) * | 2019-12-17 | 2022-09-06 | 三得利控股株式会社 | 硫酸软骨素合成促进用组合物 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2549461C2 (ru) * | 2013-01-11 | 2015-04-27 | Общество С Ограниченной Ответственностью "Парафарм" | Способ и препарат для лечения артритов и артрозов |
RU2548776C2 (ru) * | 2013-01-11 | 2015-04-20 | Общество С Ограниченной Ответственностью "Парафарм" | Способ и препарат для ускорения консолидации переломов костей |
RU2466733C1 (ru) * | 2011-03-16 | 2012-11-20 | Общество С Ограниченной Ответственностью "Парафарм" | Лекарственное средство |
RU2585108C1 (ru) * | 2015-06-01 | 2016-05-27 | Волков Андрей Евгеньевич | Композиция для восстановления хрящевой и костной ткани при остеопорозе |
RU2601112C1 (ru) * | 2015-06-08 | 2016-10-27 | Волков Андрей Евгеньевич | Способ восстановления хрящевой и костной ткани при остеопорозе |
RU2593018C1 (ru) * | 2015-10-28 | 2016-07-27 | Общество С Ограниченной Ответственностью "Парафарм" | Способ лечения остеоартроза |
KR101775662B1 (ko) | 2017-01-25 | 2017-09-19 | 주식회사 구펍 | 기능성 사료 조성물 및 그 제조 방법 |
KR101921309B1 (ko) * | 2017-06-05 | 2018-11-22 | 전남대학교산학협력단 | 바이셀라 사이베리아 균주를 포함하는 충치 예방 또는 개선용 조성물 |
RU2686448C1 (ru) * | 2018-04-16 | 2019-04-25 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" | Способ приготовления биологически активной добавки для животных и биологически активная добавка для животных на его основе |
CN110447766B (zh) * | 2019-09-11 | 2023-05-26 | 广东省农业科学院动物科学研究所 | 一种提高肉质的黄羽肉鸡饲料 |
CN114343061B (zh) * | 2022-01-13 | 2023-07-25 | 山东益得来生物科技有限公司 | 一种用于改善畜禽骨质和肉品质的组合物 |
CN116585300B (zh) * | 2023-05-30 | 2024-04-19 | 苏州大学附属第一医院 | 洋蓟素在制备预防或治疗激素性股骨头坏死药物中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001001996A1 (en) * | 1999-06-29 | 2001-01-11 | University Of Western Australia | Compositions and methods for treating or preventing osteoporosis |
CN1602159A (zh) * | 2001-12-11 | 2005-03-30 | 雀巢产品有限公司 | 用于促进骨生长及维持骨健康的组合物 |
CN101111244A (zh) * | 2004-12-31 | 2008-01-23 | 株式会社太平洋 | 含有山奈酚和槲皮素的透明质酸生成促进用组合物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1211024A (en) * | 1916-09-08 | 1917-01-02 | Albert L Wilson | Woodworking-vise. |
KR20030002377A (ko) * | 2001-06-29 | 2003-01-09 | 동화약품공업주식회사 | 골다공증 예방 및 치료용 약제 조성물 |
AU2007221853A1 (en) * | 2001-07-23 | 2007-10-25 | Nutracea Incorporated | Methods for treating joint inflammation, pain, and loss of mobility |
EP1325682A1 (en) * | 2001-12-11 | 2003-07-09 | Societe Des Produits Nestle S.A. | Food or pet food composition containing plant extracts for maintenance of bone health and prevention or treatment of bone diseases |
RU2220737C1 (ru) * | 2003-03-07 | 2004-01-10 | ЗАО "Русско-Дальневосточный продукт" | Лечебно-профилактическая композиция "остеомакс экстра" для улучшения функционального состояния опорно-двигательного аппарата |
RU2240131C1 (ru) * | 2003-04-04 | 2004-11-20 | Аладьев Сергей Иванович | Средство "артровит" для профилактики и лечения артритов и артрозов |
RU2239438C1 (ru) | 2003-12-30 | 2004-11-10 | ОАО "Нижегородский химико-фармацевтический завод" | Средство для лечения болезней суставов |
RU2353349C2 (ru) | 2007-04-18 | 2009-04-27 | Общество с ограниченной ответственностью "Фармацевтические технологии" | Средство для лечения болезней суставов |
RU2349339C1 (ru) | 2007-07-12 | 2009-03-20 | Валентина Васильевна Малиновская | Средство, обладающее иммуномодулирующим, антивирусным, антибактериальным, антиоксидантным, мембраностабилизирующим, стимулирующим регенерацию хрящевой и соединительной ткани свойствами |
RU2383356C1 (ru) * | 2008-09-25 | 2010-03-10 | Общество с ограниченной ответственностью "Производственно-коммерческая фирма "Две линии" | Наружное средство для местного применения с термоэффектом (варианты) |
RU2390270C1 (ru) * | 2009-03-13 | 2010-05-27 | Общество С Ограниченной Ответственностью "Парафарм" | Биологически активная добавка к пище |
RU2412616C1 (ru) * | 2009-11-30 | 2011-02-27 | Общество С Ограниченной Ответственностью "Парафарм" | Биологически активная добавка к пище для профилактики заболеваний остеопорозом |
-
2011
- 2011-07-05 RU RU2011127494/15A patent/RU2509569C2/ru active
-
2012
- 2012-03-07 UA UAA201315604A patent/UA111615C2/uk unknown
- 2012-07-03 WO PCT/RU2012/000528 patent/WO2013006094A2/ru active Application Filing
- 2012-07-03 PT PT12807575T patent/PT2730286T/pt unknown
- 2012-07-03 DK DK12807575.1T patent/DK2730286T3/en active
- 2012-07-03 CA CA2840895A patent/CA2840895A1/en not_active Abandoned
- 2012-07-03 US US14/130,461 patent/US20140287058A1/en not_active Abandoned
- 2012-07-03 EP EP12807575.1A patent/EP2730286B1/en active Active
- 2012-07-03 CN CN201280033364.9A patent/CN103796661A/zh active Pending
- 2012-07-03 PL PL12807575T patent/PL2730286T3/pl unknown
- 2012-07-03 CN CN201811490135.5A patent/CN109364194A/zh active Pending
- 2012-07-03 IN IN428CHN2014 patent/IN2014CN00428A/en unknown
- 2012-07-03 RS RS20181106A patent/RS57684B1/sr unknown
- 2012-07-03 HU HUE12807575A patent/HUE039880T2/hu unknown
- 2012-07-03 EA EA201400103A patent/EA031357B1/ru unknown
- 2012-07-03 ES ES12807575.1T patent/ES2688368T3/es active Active
-
2013
- 2013-12-30 IL IL23024513A patent/IL230245B/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001001996A1 (en) * | 1999-06-29 | 2001-01-11 | University Of Western Australia | Compositions and methods for treating or preventing osteoporosis |
CN1602159A (zh) * | 2001-12-11 | 2005-03-30 | 雀巢产品有限公司 | 用于促进骨生长及维持骨健康的组合物 |
CN101111244A (zh) * | 2004-12-31 | 2008-01-23 | 株式会社太平洋 | 含有山奈酚和槲皮素的透明质酸生成促进用组合物 |
Non-Patent Citations (2)
Title |
---|
侯立飞等: "中药有效成分治疗类风湿关节炎研究进展", 《中国野生植物资源》 * |
杜迎刚: "蜜蜂雄蜂幼虫的功能活性研究", 《中国优秀博硕士学位论文全文数据库(硕士)农业科技辑》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104721678A (zh) * | 2014-07-12 | 2015-06-24 | 广东医学院 | 高良姜提取物在制备抗骨质疏松保健食品及药品方面的应用 |
CN104721678B (zh) * | 2014-07-12 | 2020-11-27 | 广东医科大学 | 高良姜提取物在制备抗骨质疏松药品方面的应用 |
CN106615132A (zh) * | 2016-11-28 | 2017-05-10 | 山东坤泰生物科技有限公司 | 一种改善骨质疏松的配制型含乳饮料及其制备方法 |
CN106511336A (zh) * | 2016-12-16 | 2017-03-22 | 常州南京大学高新技术研究院 | Harrisotone A衍生物的组合物在抗骨质疏松药物中的应用 |
CN109260514A (zh) * | 2018-08-31 | 2019-01-25 | 湖南大学 | 一种花旗松素改性纤维支架及其制备方法和应用 |
CN115023150A (zh) * | 2019-12-17 | 2022-09-06 | 三得利控股株式会社 | 硫酸软骨素合成促进用组合物 |
CN115023150B (zh) * | 2019-12-17 | 2024-04-26 | 三得利控股株式会社 | 硫酸软骨素合成促进用组合物 |
Also Published As
Publication number | Publication date |
---|---|
RS57684B1 (sr) | 2018-11-30 |
EA201400103A1 (ru) | 2016-08-31 |
PT2730286T (pt) | 2018-10-22 |
EP2730286A4 (en) | 2015-06-17 |
IL230245B (en) | 2019-11-28 |
CA2840895A1 (en) | 2013-01-10 |
HUE039880T2 (hu) | 2019-02-28 |
EP2730286B1 (en) | 2018-06-20 |
PL2730286T3 (pl) | 2018-12-31 |
DK2730286T3 (en) | 2018-10-15 |
UA111615C2 (uk) | 2016-05-25 |
RU2011127494A (ru) | 2013-01-10 |
CN109364194A (zh) | 2019-02-22 |
EP2730286A2 (en) | 2014-05-14 |
RU2509569C2 (ru) | 2014-03-20 |
IN2014CN00428A (zh) | 2015-04-03 |
WO2013006094A3 (ru) | 2013-05-30 |
WO2013006094A2 (ru) | 2013-01-10 |
ES2688368T3 (es) | 2018-11-02 |
US20140287058A1 (en) | 2014-09-25 |
EA031357B1 (ru) | 2018-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103796661A (zh) | 用于维持骨骼健康以及治疗骨关节炎和关节的骨关节病的组合物 | |
RU2314717C2 (ru) | Композиция для стимулирования роста костей и поддержания здоровья костей | |
CN107319525A (zh) | 一种减肥减脂专用型临床营养配方及其制备方法 | |
CN106135890A (zh) | 一种有助于骨关节健康的营养组合物 | |
JP2005512553A (ja) | 骨健康のための植物抽出物を含む食品又はペットフード組成物 | |
CN102014893A (zh) | 用于治疗软骨障碍的多酚类 | |
CN107440102A (zh) | 一种更年期女性专用型临床营养配方及其制备方法 | |
CN105535163A (zh) | 一种改善畜禽及水产品风味品质的中药组合物 | |
KR102444911B1 (ko) | 산나물 추출물을 유효성분으로 하는 근육관련 질환 예방 또는 치료, 근기능 개선 또는 운동수행능력 개선용 조성물 | |
ES2790428T3 (es) | Utilización de una asociación de dos compuestos para el tratamiento y/o la prevención de trastornos óseos | |
CN105535094A (zh) | 一种促进畜禽和鱼类生产性能的中药组合物 | |
CN105053621A (zh) | 一种黄斑篮子鱼稚鱼配合饲料及其制备方法 | |
KR100278206B1 (ko) | 성장촉진용 건강보조식품 조성물 | |
JP2002187846A (ja) | 組成物及びそれを含有する食品、抗関節炎剤、抗リュウマチ剤又は飼料 | |
CN107669980A (zh) | 一种改善骨关节健康的营养组合物及其制备方法与应用 | |
JP2002145794A (ja) | 抗関節炎もしくは抗リュウマチ製剤、食品又は飼料 | |
KR101908850B1 (ko) | 구기자를 포함하는 항비만 한방조성물 및 그 제조방법 | |
KR20190101632A (ko) | 한약재를 포함하는 항염용 조성물 | |
KR20180133271A (ko) | 생약 추출물 및 분말을 이용한 강정제와 그에 따른 제조방법 | |
KR102113431B1 (ko) | 한약재를 포함하는 항염용 조성물 및 그 제조방법 | |
JP7385256B2 (ja) | 経口組成物 | |
Noor et al. | Efficacy of licorice extract added to drinking water in improving productive efficiency and some qualitative traits of carcass for broilers. | |
CN106107986A (zh) | 一种骨伤患者特殊医学用途配方食品 | |
PL244069B1 (pl) | Suplement diety dla zwierząt | |
CN114128786A (zh) | 一种用于动物消食的制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140514 |